Abstract Evidence is emerging that inflammation plays a key role in the pathophysiology of ischemic stroke (IS). The aim of this study was to explore, for the first time, the relationship between IL-1β −31 T/C polymorphism and the risk of ischemic stroke (IS) among patients with type 2 diabetes mellitus (T2DM). One hundred ninety-six patients with IS (117 diabetics and 79 nondiabetics) and 192 controls were recruited to enroll in this study. IL-1β genotyping was performed by PCR-RFLP technique. After adjusting for sex, age, smoking, obesity, dyslipidemia, and hypertension, there was no significant difference in the distribution of IL-1β −31 T/C genotypes and allele frequencies between IS patients with or without type 2 diabetes mellitus and control group (p>0.05). Moreover, a significant positive correlation between serum IL-1β level and glucose (p1=0.044) was showed. In addition, serum levels of IL-1β were found to be higher among TT genotype carriers than TC and CC genotype carriers in ischemic stroke patients with or without T2DM but these differences were not significant. These results indicate that IL-1β gene polymorphism might not be a risk factor in the development of ischemic stroke in Tunisian population.
Introduction
Ischemic stroke constitutes approximately 85 % of all strokes and has caused a large number of deaths globally (Rosand et al. 2006; Strong et al. 2007) . Scientific evidences suggested inflammation as a key factor in the pathological response of stroke (Denes et al. 2010; Hopkins et al. 2012) . The majority of inflammatory reactions to cerebral ischemia are mediated by cytokines which increase in the central nervous system (CNS) and the systemic circulation in patients with ischemic stroke (IS) (Emsley et al. 2003; Bharosay et al. 2011) . Type 2 diabetes mellitus (T2DM) has been recognized as an immunemediated disease leading to impaired insulin signaling and selective destruction of insulin-producing β-cells in which cytokines play an important role. Diabetes is an independent risk factor for stroke. Compared with nondiabetic patients, diabetic patients have at least twice the risk for stroke, and approximately 20 % of diabetic patients will die from stroke, making it one of the leading causes of death. Diabetes duration has also been shown to increase the risk of ischemic stroke disease, with every year of diabetes duration increasing the risk by 3 % (Banerjee et al. 2012) . Interleukin (IL)-1β is a proinflammatory cytokine that induces the production of cytokines and chemokines and plays an important role in inflammatory processes. It contributes to the development of vascular damage and atherosclerosis by stimulating cell proliferation and differentiation and the release of matrix-degrading enzymes. A study of Licata et al. (2009) showed that patients with IS have higher plasma levels of IL-1β compared with control subjects. IL-1β is located in 70-110 kb region of chromosome 2q13-21, including 7 exons and 6 introns. At least 20 SNPs were reported in the region of IL-1β. The IL-1β −31 T/C substitution located in the TATA box motif in the promoter region of the gene IL-1β was found to markedly affect the binding of several transcription factors (El-Omar et al. 2000; Lind et al. 2007 ) and thereby affect the transcription activity of IL-1β (Chen et al. 2006) . To the author's best knowledge, this is the first report to study on the genetic level the potential relationship between −31 T/C promoter polymorphism in the IL-1β gene and the risk of ischemic stroke. We therefore investigated, for the first time, the effect of this polymorphism on serum level of IL-1β, lipid profile, and the risk of ischemic stroke in Tunisian patients with and without T2DM.
Materials and Methods

Subjects
Informed consent was obtained from all participants, and this study was approved by our Institutional Research Committee. A total of 196 patients with ischemic stroke (IS) were enrolled in this study, among whom 117 subjects presented with type 2 diabetes mellitus (T2DM), 79 nondiabetic subjects. All patients were recruited from the Emergency Department at Fattouma Bourguiba University Hospital in Monastir, Tunisia. One hundred ninety-two individuals with normal glucose and free of any history of obesity, hypertension, dyslipidemia, diabetes mellitus, or CAD were included in the study as controls. Healthy subjects consisting of blood donors of Tunisian origin were assessed by direct interview by two experienced neurologists for any neurological disorders. All participants completed a structured questionnaire as performed previously by Meschia et al. (2000) in order to verify the stroke-free status, and a complete clinical history, including stroke risk factors, was taken for all participants.
Laboratory Measurements and Techniques
Serum total cholesterol, HDL-C, and triglycerides were measured using enzymatic methods on Beckman autoanalyzer (Randox, Antrim, UK). LDL-C cholesterol was calculated using Friedewald's formula (Rader et al. 1994) . Serum apoA-I and apoB were determined by the use of a highly sensitive immunonephelometric assay (BNII-Dade Behring). Serum IL-1β levels were assessed by enzyme-linked immunosorbent assay (ELISA) using ELISA kits KHC0012 (192 tests) ].
IL-1β Genotyping
Genomic DNA was extracted via blood sample from each subject, and the quality of extracts was checked electrophoretically. Genetic variant in the promoter region of the IL-1β gene was identified by using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) in all patients and controls using the restriction enzyme Alu I. For −31 T/C polymorphic site, a 420-bp PCR fragment was amplified using the primers as described in Kimura et al. (2004) . PCR conditions were as follows: 96°C for 1 min, followed by 35 cycles of 94°C for 50 s, 50°C for 1 min, 72°C for 40 s, and final elongation at 72°C for 10 min. The PCR products were digested with AluI. The allele T has three cut sites resulting in four fragments of the following sizes: 247, 97, 57, and 20 bp. The C allele has two cut sites, resulting in fragments of sizes 344, 57, and 20 bp.
Statistical Analysis
Statistical analysis was performed using SPSS version 17.0 software. The Hardy-Weinberg equilibrium was performed using chi-square test. Data were expressed as mean±SD (continuous variables) or as percentages of total (categorical variables). We used a one-way analysis of variance (ANOVA) and Student t test to evaluate the relationships between IL-1β genotypes and quantitative variables. Correlations were tested by using Pearson's test. The differences in anthropometric and biochemical parameters among the diabetic ischemic stroke patients, nondiabetic ischemic stroke patients, and healthy controls were examined by unpaired Student t test. The effects of genotypes were analysed and presented for all three genotype groups (TT, TC, and CC). We measured the independent contribution of the polymorphism to the risk of ischemic stroke using a stepwise logistic regression model, and p value was obtained after adjusting for covariates. All p values were two-tailed, and significance level was set at p<0.05.
Results
Clinical Characteristics of the Study Population
Clinical characteristics of ischemic stroke patients and control groups are shown in Table 1 . There were no differences in the mean age, BMI, and sex between the patients with or without diabetes and control groups. The results presented were obtained from the analysis of the whole population (men and women). All comparisons were re-done after dichotomization of men, and no differences in the results were revealed (data not shown). Compared with controls, the diabetic ischemic stroke patient group had a higher prevalence of conventional risk factors for stroke, including high levels of systolic blood pressure (SBP; p<0.001), diastolic blood pressure (DBP; p <0.001), smoking (p <0.05), glucose (p < 0.001), triglycerides (TG) (p = 0.009), higher level of ApoB (p<0.001), lower levels of HDL-C (p<0.05), and ApoA-I (p<0.001), whereas LDL-C and total cholesterol levels were not significantly different (p>0.05). SBP, DBP, glucose, TG level (p = 0.004), and ApoB (p<0.001) were found to be higher in the nondiabetic ischemic stroke patient group than in the controls, in addition to a lower level of ApoA-I (p<0.001). However, HDL-C level (p=0.55), LDL-C level (p=0.94), and total cholesterol (p=0.54) were not significantly different (Table 1) .
Variation of Serum IL-1β Levels in Controls and in Ischemic Stroke Patients With or Without T2DM
A significant increase in the concentration of IL-1β was showed in diabetic patients with IS compared to controls (8.20±2.85 versus 0.97±0.65) (p<0.001). Similarly, for nondiabetic stroke patients, the concentration of IL-1β was showed to be higher compared to controls (6.62±3.45 versus 0.97±0.65) (p<0.001). In addition, serum levels of IL-1β were significantly higher in diabetic patients compared to nondiabetic patients (p=0.048) (Fig. 1) .
Lipoprotein Profile and Serum IL-1β Levels According to the IL-1β −31 T/C Genotypes
In IS patients with T2DM, Pearson's correlation coefficient showed a significant positive correlation between serum IL-1β level and glucose (p1=0.044). However, serum level of IL-1β was not correlated to other biochemical parameters. Moreover, there was no significant correlation between the level of IL-1β and biochemical parameters in IS patients without T2DM. The baseline characteristics among the genotype groups in controls and in ischemic stroke patients with or without T2DM were compared among three genotype groups by ANOVA test. After controlling for sex, age, smoking, obesity, dyslipidemia, and hypertension, no significant difference p2 serum IL-1β levels versus lipid and lipoprotein concentrations in T2DM (−) IS; p* adjusted for sex, age, smoking, obesity, dyslipidemia, and hypertension; p* comparisons among TT, TC, and CC genotypes; r correlation coefficient of serum IL-1β levels with lipoprotein profile in BMI and plasma concentrations of total cholesterol, TG, LDL-C, HDL-C, ApoA-I, and ApoB was observed in ischemic stroke patients with or without T2DM and controls between IL-1β genotypes. In addition, serum levels of IL-1β were found to be higher among TT genotype carriers than TC and CC genotypes carriers in ischemic stroke patients with or without T2DM but these differences were not significant (p1, p2, and p3>0.05) ( Table 2 ).
The −31 T/C Polymorphism and the Risk of Ischemic Stroke
The genotype distribution was in Hardy-Weinberg equilibrium (χ 2 =0.125, p=0.841). The frequencies of IL-1β −31 T/C T allele carriers and C allele carriers were 0.657 and 0.341, respectively, among the diabetic ischemic stroke patients, 0.632 and 0.366, respectively, among the nondiabetic ischemic stroke patients and 0.538 and 0.459, respectively, among the control subjects. As shown in Table 3 , the C allele carriers in the healthy group were higher than those in IS patients with T2DM. Moreover, IS patients with T2DM carrying either one or two copies of the C allele had a reduced IS risk compared to the TT homozygotes but this difference was not significant (AOR=0.61; 95 % CI 0.48 to 1.10; p=0.064). No significant difference was also observed in C allele frequency between nondiabetic ischemic patients and controls (AOR=0.53; 95 % CI 0.35 to 1.02; p = 0.145) after adjusting for sex, age, smoking, obesity, dyslipidemia, and hypertension (Table 3) .
Discussion
This is the first study conducted on the Tunisian population to investigate the association between serum level and polymorphism −31 T/C of IL-1β and the risk of ischemic stroke among patients with type 2 diabetes. In the current study, we have reported, for the first time, a significant increase in the concentration of IL-1β in diabetic and nondiabetic stroke patients compared to controls. In addition, serum level of IL-1β was significantly higher in diabetic patients than in nondiabetic patients. A significant positive correlation was showed between serum level of IL-1β and the rate of blood glucose in diabetic patients with ischemic stroke. The role of inflammatory responses in the pathogenesis of type 2 diabetes was increased in recent years. IL-1β has been reported to contribute to the failure of β cells (Ehses et al. 2007 ). These cells secreted IL-1β after glucose stimulation (Maedler et al. 2002) . Additionally, IL-1β stimulated its own production in β cells (Böni-Schnetzler et al. 2008 ) and attracted macrophages that could act as an additional source of IL-1β and other cytokines. In our study, we have not found a significant association between the polymorphism −31 T/C and the risk of ischemic stroke. However, Zhu et al. (2009) reported that −31 T allele carriers have a high risk of coronary heart disease compared to −31C allele carriers. Moreover, Mattuzzi et al. (2007) showed a significant association between the polymorphism −31 T/C of IL-1β and severity of systemic sclerosis. Previous studies have indicated that −31 T/C polymorphic site was a part of the TATA box, and the presence of the T allele was associated with increase in the production of IL-1β compared to the C allele (El-Omar et al. 2000; Chen et al. 2006 ). On the other hand, some reports not only did not show any significant association between −31 T/ C polymorphism and the production of IL-1β in vitro (Santtila et al. 1998 ), but they also noted that C allele was associated with high expression of IL-1β in vivo (Hwang et al. 2002 ). In the current study, serum levels of IL-1β were found to be higher among TT genotype carriers as compared with TC and CC genotypes carriers in the group of diabetic and nondiabetic patients with ischemic stroke but these differences were not significant. A study by Kimura et al. (2004) found that the mRNA expression of IL-1β was elevated in TT genotype carriers than CC and CT genotypes carriers. It was therefore suggested that carriers of the TT genotype have a higher production of IL-1β compared to TC or CC genotype carriers. Results were not entirely consistent with each other, which may be related to research methods and sample size. Inflammation seems to be an important mechanism in cerebrovascular disease because systemic markers of inflammation have been consistently associated with risk of ischemic (Danesh et al. 1998) . However, it is still unclear if the inflammation is a causal mechanism or a secondary phenomenon induced by the ischemic process and if it affects the process of atherosclerosis.
Conclusions
In summary, to our best knowledge, this work is the first study addressing the relationship between IL-1β −31 T/C polymorphism and the risk of ischemic stroke among patients with T2DM. However, no statistical association was observed regarding this polymorphism in this study, which indicates that IL-1β gene polymorphism might not be a risk factor in the development of ischemic stroke in Tunisian population. Further investigations are needed to conclusively assess this.
